Clay Siegall’s Early Life Career Journey
About Clay Siegall
Dr. Clay Siegall established Seattle Genetics, the biggest biotech in Washington in 1998. The company has a chief drug, Adcetris, which cures Hodgkin lymphoma, a cancer of the lymph system and can affect other organs. The drug was recently approved by the U.S. Food and Drug Administration. Clay Siegall holds a Bachelor of Science in Zoology from Maryland University. Later on, he went to George Washington University to pursue his Ph.D. in Genetics.
Dr. Siegall’s educational background has been instrumental in his cumulative professional achievements. By joining forces with Takeda, Dr. Siegall has gained insight on global markets and has recently opened an office in Switzerland. The new office will help Dr. Siegall’s company to improve its presence in the international market. Dr. Clay Siegall has over two decades of experience in cancer research and development of therapeutic drugs.
Dr. Siegall worked at Mirna Therapeutics from January 2013 to December 2016. Since January 2014, Dr. Siegall has been a board member of Seattle Genetics. Currently, he serves as the company’s President and Chief Executive Officer. Besides, he serves as the Director on the board of the Alder BioPharmaceuticals. Before starting Seattle Genetics, Dr. Clay Siegall worked for the National Cancer Institute and the National Institutes of Health and Bristol-Myers Squibb Pharmaceutical Research Institute.
As Seattle Genetics’ Chairman of the Board of Directors, Dr. Siegall has been instrumental in its success. During his tenure, Seattle Genetics revolutionized the world of cancer treatment through antibody-based cancer treatment therapies. Dr. Siegall and Matthew Fust were recently appointed to the Board of Directors of Ultragenyx. They bring an extensive experience in cancer treatment even as Ultragenyx continues to grow. Both have a track record of success in the biopharmaceutical industry. Since its inception in 2010, Ultragenyx specializes in developing treatment therapies for metabolic infections. Under Dr. Clay Siegall’s leadership, Seattle Genetics has continued to invest in cancer research industry. Since commencing his practice in biomedical studies, Dr. Siegall dedicates to finding a remedy for cancer and improving lives of cancer patients. Besides, he demonstrates leadership by helping Seattle Genetics raise funds through public and private capitalization. Dr. Clay Siegall’s incredible leadership style has helped Seattle Genetics to continue developing antibody-based cancer treatment therapeutics.